{"DataElement":{"publicId":"6815891","version":"1","preferredName":"Prostate Carcinoma Local Disease Extent Category","preferredDefinition":"The category assigned to describe the location of the carcinoma within and around the prostate gland.","longName":"6815884v1.0:6815886v1.0","context":"MCL","contextVersion":"1","DataElementConcept":{"publicId":"6815884","version":"1","preferredName":"Prostate Carcinoma Local Disease or Disorder Extent","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_Of or belonging to a restricted area or locality._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._The range, magnitude, or distance over which a thing spans an interval of distance, space, or time.","longName":"2744055v1.0:2688162v1.0","context":"MCL","contextVersion":"1","ObjectClass":{"publicId":"2744055","version":"1","preferredName":"Prostate Carcinoma","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8AEEC8-FDF2-03F8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-23","modifiedBy":"ONEDATA","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2688162","version":"1","preferredName":"Local Diseases and Disorders Extent","preferredDefinition":"Of or belonging to a restricted area or locality.:A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.:The range, magnitude, or distance over which a thing spans an interval of distance, space, or time.","longName":"C67263:C2991:C25332","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Local","conceptCode":"C67263","definition":"Of or belonging to a restricted area or locality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Extent","conceptCode":"C25332","definition":"The range, magnitude, or distance over which a thing spans an interval of distance, space, or time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C0EAD8C-4748-0635-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-10-09","modifiedBy":"ONEDATA","dateModified":"2007-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"MCL:Molecular and Cellular Characterization of Screened Lesions","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8D59727A-A9FB-10A1-E053-F662850AB126","latestVersionIndicator":"Yes","beginDate":"2019-07-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-10","modifiedBy":"COLBERTM","dateModified":"2022-03-18","changeDescription":"3/18/22 mr Released per DCT and SME.   7-10-19 tt created for prostate content.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6815886","version":"1","preferredName":"Prostate Carcinoma Extent Category","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_The range, magnitude, or distance over which a thing spans an interval of distance, space, or time._A grouping of items based on some commonality or by user defined characteristics.","longName":"6815886v1.0","context":"MCL","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Extraprostatatic extension","valueDescription":"Extraprostatic Extension","ValueMeaning":{"publicId":"6815887","version":"1","preferredName":"Extraprostatic Extension","longName":"6815887","preferredDefinition":"A finding indicating the presence of a prostatic carcinoma that has invaded the prostatic capsule and has spread to nearby tissues or distant anatomic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extraprostatic Extension","conceptCode":"C162259","definition":"A finding indicating the presence of a prostatic carcinoma that has invaded the prostatic capsule and has spread to nearby tissues or distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D597F0F-CE1E-5781-E053-F662850A0196","latestVersionIndicator":"Yes","beginDate":"2019-07-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-10","modifiedBy":"ONEDATA","dateModified":"2019-07-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8D597F0F-CE37-5781-E053-F662850A0196","beginDate":"2019-07-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-10","modifiedBy":"ONEDATA","dateModified":"2019-07-10","deletedIndicator":"No"},{"value":"Organ confined","valueDescription":"Localized Carcinoma","ValueMeaning":{"publicId":"6815888","version":"1","preferredName":"Localized Carcinoma","longName":"6815888","preferredDefinition":"A carcinoma which is confined to a specific anatomic site and has not spread to other sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Localized Carcinoma","conceptCode":"C7625","definition":"A carcinoma that is confined to a specific site without evidence of spread to other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D597F0F-CE43-5781-E053-F662850A0196","latestVersionIndicator":"Yes","beginDate":"2019-07-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-10","modifiedBy":"ONEDATA","dateModified":"2019-07-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8D597F0F-CE5C-5781-E053-F662850A0196","beginDate":"2019-07-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-10","modifiedBy":"ONEDATA","dateModified":"2019-07-10","deletedIndicator":"No"},{"value":"Not reported","valueDescription":"Not Reported","ValueMeaning":{"publicId":"2572231","version":"1","preferredName":"Not Reported","longName":"2572231","preferredDefinition":"Not provided or available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Reported","conceptCode":"C43234","definition":"Not provided or available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E734-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-11-16","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD236659-B2CA-23B1-E053-4EBD850A6AA3","beginDate":"2021-09-29","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-29","modifiedBy":"ONEDATA","dateModified":"2021-09-29","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"5682953","version":"1","preferredName":"Unknown","longName":"5682953","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4645-0FC6-0802-E053-F662850AB305","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD236659-B2D4-23B1-E053-4EBD850A6AA3","beginDate":"2021-09-29","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-29","modifiedBy":"ONEDATA","dateModified":"2021-09-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6815885","version":"1","preferredName":"Prostate Carcinoma Extent Category","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002:The range, magnitude, or distance over which a thing spans an interval of distance, space, or time.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C4863:C25332:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Extent","conceptCode":"C25332","definition":"The range, magnitude, or distance over which a thing spans an interval of distance, space, or time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D597F0F-CDF3-5781-E053-F662850A0196","latestVersionIndicator":"Yes","beginDate":"2019-07-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-10","modifiedBy":"ONEDATA","dateModified":"2019-07-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"MCL:Molecular and Cellular Characterization of Screened Lesions","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8D597F0F-CE04-5781-E053-F662850A0196","latestVersionIndicator":"Yes","beginDate":"2019-07-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-10","modifiedBy":"COLBERTM","dateModified":"2022-03-18","changeDescription":"3/18/22 mr Released per DCT and SME.   9/29/21 mr Added Unknown and NR for MCL prostate.  7-10-19 tt created for prostate content.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506113","version":"1","longName":"Prostate","context":"MCL","ClassificationSchemeItems":[{"publicId":"7781145","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]},{"publicId":"6437797","version":"1","longName":"Pre-Cancer Atlas Pilot","context":"MCL","ClassificationSchemeItems":[{"publicId":"7001794","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]}],"AlternateNames":[{"name":"local_extent","type":"MCL Alt Name","context":"MCL"}],"ReferenceDocuments":[{"name":"Local extent","type":"Preferred Question Text","description":"Local extent","url":null,"context":"MCL"},{"name":"MCL-Template Name","type":"Data Collection Template","description":"prostate_v0_13aug2020.xlsx","url":"https://mcl.nci.nih.gov/resources/standards/mcl-cdes","context":"MCL"}],"origin":"MCL:Molecular and Cellular Characterization of Screened Lesions","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8D5A16D2-5542-58FA-E053-F662850A932B","latestVersionIndicator":"Yes","beginDate":"2019-07-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-10","modifiedBy":"COLBERTM","dateModified":"2022-03-18","changeDescription":"3/18/22 mr Released per DCT and SME.   10/13/21 mr Updated definition.   9/29/21 mr Updated PVs, added alt name, ref doc. Per MCL DD.  7-10-19 tt created for prostate content.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}